Paper29334366
Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.
Menna P and 5 others. Chemotherapy, 2018. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy. Papers, record 29334366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29334366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acute Kidney Injury | Major topic |
| Anti-Bacterial Agents | Major topic |
| Colistin | Major topic |
| Aged | |
| Area Under Curve | |
| Critical Illness | |
| Gram-Negative Bacteria | |
| Gram-Negative Bacterial Infections | |
| Humans | |
| Male | |
| Microbial Sensitivity Tests | |
| Middle Aged | |
| Prognosis | |
| Pseudomonas aeruginosa | |
| ROC Curve | |
| Renal Dialysis | |
| Renal Replacement Therapy |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42490869 | Pharmacokinetics of polymyxin drugs in special populations. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42490869 | PubMed |
| 39340688 | High-dose colistin pharmacokinetics in critically ill patients receiving continuous renal replacement therapy. | Ann Intensive Care | 2024 | https://conductscience.org/library/papers/39340688 | PubMed |
| 37518089 | Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: protocol for the COL-ECMO2022 trial - a prospective, non-randomised, open-label phase IV pharmacokinetic clinical trial. | BMJ Open | 2023 | https://conductscience.org/library/papers/37518089 | PubMed |
| 36978303 | Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/36978303 | PubMed |
| 35722356 | Plasma concentrations of Colistin sulfate in a patient with septic shock on extracorporeal membrane oxygenation and continuous renal replacement therapy: a case report. | Ann Transl Med | 2022 | https://conductscience.org/library/papers/35722356 | PubMed |
| 32547394 | Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32547394 | PubMed |
| 31344885 | An Approach to Measuring Colistin Plasma Levels Regarding the Treatment of Multidrug-Resistant Bacterial Infection. | Antibiotics (Basel) | 2019 | https://conductscience.org/library/papers/31344885 | PubMed |
| 31109983 | A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31109983 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29334366
GET https://conductscience.org/api/papers/v1/29334366/authors